100 related articles for article (PubMed ID: 15371781)
1. ErbB2 is a tumor associated antigen and a suitable therapeutic target in Wilms tumor.
Pinthus JH; Fridman E; Dekel B; Goldberg I; Kaufman-Francis K; Eshhar Z; Harmelin A; Rechavi G; Mor O; Ramon J; Mor Y
J Urol; 2004 Oct; 172(4 Pt 2):1644-8. PubMed ID: 15371781
[TBL] [Abstract][Full Text] [Related]
2. Amplification and expression of EGFR and ERBB2 in Wilms tumor.
Vasei M; Modjtahedi H; Ale-Booyeh O; Mosallaei A; Kajbafzadeh AM; Shahriari M; Ghaderi AA; Soleymanpour H; Kosari F; Moch H; Sauter G
Cancer Genet Cytogenet; 2009 Oct; 194(2):88-95. PubMed ID: 19781441
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Wilms tumor xenograft progression by halofuginone is accompanied by activation of WT-1 gene expression.
Pinthus JH; Sheffer Y; Nagler A; Fridman E; Mor Y; Genina O; Pines M
J Urol; 2005 Oct; 174(4 Pt 2):1527-31. PubMed ID: 16148645
[TBL] [Abstract][Full Text] [Related]
4. Expression of cyclooxygenase-2 in Wilms tumor: immunohistochemical study using tissue microarray methodology.
Fridman E; Pinthus JH; Kopolovic J; Ramon J; Mor O; Mor Y
J Urol; 2006 Oct; 176(4 Pt 2):1747-50. PubMed ID: 16945639
[TBL] [Abstract][Full Text] [Related]
5. Distinctive properties of an anaplastic Wilms' tumor and its associated epithelial cell line.
Hazen-Martin DJ; Re GG; Garvin AJ; Sens DA
Am J Pathol; 1994 May; 144(5):1023-34. PubMed ID: 8178926
[TBL] [Abstract][Full Text] [Related]
6. Nephroblastoma (Wilms' tumor): a model system of aberrant renal development.
Re GG; Hazen-Martin DJ; Sens DA; Garvin AJ
Semin Diagn Pathol; 1994 May; 11(2):126-35. PubMed ID: 7809506
[TBL] [Abstract][Full Text] [Related]
7. A nude mouse Wilms' tumor line (KCMC-WT-1) derived from an aniridia patient with monoalleleic partial deletion of chromosome 11p.
Nagashima Y; Nishihira H; Miyagi Y; Tanaka Y; Sasaki Y; Nishi T; Imaizumi K; Aoki I; Misugi K
Cancer; 1996 Feb; 77(4):799-804. PubMed ID: 8616775
[TBL] [Abstract][Full Text] [Related]
8. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors.
Petit AM; Rak J; Hung MC; Rockwell P; Goldstein N; Fendly B; Kerbel RS
Am J Pathol; 1997 Dec; 151(6):1523-30. PubMed ID: 9403702
[TBL] [Abstract][Full Text] [Related]
9. Extrarenal Wilms' tumors. A study of their relationship with classical renal Wilms' tumor using expression of WT1 as a molecular marker.
Roberts DJ; Haber D; Sklar J; Crum CP
Lab Invest; 1993 May; 68(5):528-36. PubMed ID: 8388523
[TBL] [Abstract][Full Text] [Related]
10. Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor.
Soffer SZ; Moore JT; Kim E; Huang J; Yokoi A; Manley C; O'Toole K; Stolar C; Middlesworth W; Yamashiro DJ; Kandel JJ
J Pediatr Surg; 2001 Aug; 36(8):1177-81. PubMed ID: 11479851
[TBL] [Abstract][Full Text] [Related]
11. S100A4 mRNA as a prognostic marker and therapeutic target in Wilms tumor (WT).
Li HJ; Chen YX; Wang Q; Zhang YG
Eur Rev Med Pharmacol Sci; 2014; 18(6):817-27. PubMed ID: 24706305
[TBL] [Abstract][Full Text] [Related]
12. Orthotopic Wilms tumor xenografts derived from cell lines reflect limited aspects of tumor morphology and clinical characteristics.
Mengelbier LH; Bexell D; Sehic D; Ciornei CD; Gisselsson D
Pediatr Blood Cancer; 2014 Nov; 61(11):1949-54. PubMed ID: 25044705
[TBL] [Abstract][Full Text] [Related]
13. Antibody to type I insulinlike growth factor receptor inhibits growth of Wilms' tumor in culture and in athymic mice.
Gansler T; Furlanetto R; Gramling TS; Robinson KA; Blocker N; Buse MG; Sens DA; Garvin AJ
Am J Pathol; 1989 Dec; 135(6):961-6. PubMed ID: 2556929
[TBL] [Abstract][Full Text] [Related]
14. Identification of a five-mRNA signature as a novel potential prognostic biomarker in pediatric Wilms tumor.
Lin XD; Wu YP; Chen SH; Sun XL; Ke ZB; Chen DN; Li XD; Lin YZ; Wei Y; Zheng QS; Xu N; Xue XY
Mol Genet Genomic Med; 2020 Jan; 8(1):e1032. PubMed ID: 31701684
[TBL] [Abstract][Full Text] [Related]
15. A novel animal model for the evaluation of the efficacy of drugs directed against the ErbB2 receptor on metastasis formation.
Maurer-Gebhard M; Schmidt M; Azemar M; Stöcklin E; Wels W; Groner B
Hybridoma; 1999 Feb; 18(1):69-75. PubMed ID: 10211791
[TBL] [Abstract][Full Text] [Related]
16. Topoisomerase IIalpha in Wilms' tumour: gene alterations and immunoexpression.
Tretiakova M; Turkyilmaz M; Grushko T; Kocherginsky M; Rubin C; Teh B; Yang XJ
J Clin Pathol; 2006 Dec; 59(12):1272-7. PubMed ID: 16556665
[TBL] [Abstract][Full Text] [Related]
17. Decrease in LDL receptor-related protein expression and function correlates with advanced stages of Wilms tumors.
Desrosiers RR; Rivard ME; Grundy PE; Annabi B
Pediatr Blood Cancer; 2006 Jan; 46(1):40-9. PubMed ID: 16106426
[TBL] [Abstract][Full Text] [Related]
18. Gene expression profiling of favorable histology Wilms tumors and its correlation with clinical features.
Takahashi M; Yang XJ; Lavery TT; Furge KA; Williams BO; Tretiakova M; Montag A; Vogelzang NJ; Re GG; Garvin AJ; Söderhäll S; Kagawa S; Hazel-Martin D; Nordenskjold A; Teh BT
Cancer Res; 2002 Nov; 62(22):6598-605. PubMed ID: 12438255
[TBL] [Abstract][Full Text] [Related]
19. miR-483-5p Targets MKNK1 to Suppress Wilms' Tumor Cell Proliferation and Apoptosis In Vitro and In Vivo.
Liu K; He B; Xu J; Li Y; Guo C; Cai Q; Wang S
Med Sci Monit; 2019 Feb; 25():1459-1468. PubMed ID: 30798328
[TBL] [Abstract][Full Text] [Related]
20. Polypeptide-based nanogels co-encapsulating a synergistic combination of doxorubicin with 17-AAG show potent anti-tumor activity in ErbB2-driven breast cancer models.
Desale SS; Raja SM; Kim JO; Mohapatra B; Soni KS; Luan H; Williams SH; Bielecki TA; Feng D; Storck M; Band V; Cohen SM; Band H; Bronich TK
J Control Release; 2015 Jun; 208():59-66. PubMed ID: 25660204
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
